XXXX : importance of diagnosis with molecular analysis in the neonatal period.

@entity52353 @entity34001 @entity4670 @entity15617 @entity920
@entity15617 is a @entity4670 caused by changes in @entity920 metabolism derived from mutations in the @entity34001 gene. It is characterized by physical and neurological alterations. In the neonatal period, these alterations can be nonspecific, which makes early diagnosis a challenge. Diagnosis can be suspected when there are low levels of ceruloplasmin and serum @entity920 . Molecular analysis confirms the diagnosis. Treatment is parenteral administration of @entity52353 . We report a familial case with molecular confirmation. The proband had clinical and biochemical suspicious. Treatment with @entity52353 was indicated, but initiated at the age of 2 months and 27 days only. He did not present improvements and died at 6 months. The mother became pregnant again, a male fetus was identified and @entity52353 was manufactured during pregnancy. He was born healthy, biochemical markers were reduced and treatment was indicated. Molecular analysis was performed confirming mutation in both the mother and the proband, while the other son did not have mutation, so treatment was discontinued. We support the clinical relevance of molecular confirmation for the correct diagnosis and genetic counseling, once clinical findings in the neonatal period are nonspecific and early treatment with parenteral @entity52353 must be indicated.
